MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./270/0.1/20.12.24 Stock

Warrant

DE000ME9GR30

Market Closed - Börse Stuttgart 02:58:12 2024-05-31 pm EDT
0.28 EUR +21.74% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./270/0.1/20.12.24
Current month-51.72%
1 month-51.72%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-31 0.28 +21.74%
24-05-30 0.23 -4.17%
24-05-29 0.24 -14.29%
24-05-28 0.28 -.--%
24-05-27 0.28 -3.45%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 02:58 pm EDT

More quotes

Static data

Product typeWarrant Plain-Vanilla
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN ME9GR3
ISINDE000ME9GR30
Date issued 2024-03-01
Strike 270 $
Maturity 2024-12-20 (202 Days)
Parity 10 : 1
Emission price 0.87
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.12
Lowest since issue 0.19
Spread 0.03
Spread %8.82%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
232 USD
Average target price
278.7 USD
Spread / Average Target
+20.14%
Consensus